12:00 AM
 | 
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Opaxio paclitaxel poliglumex regulatory update

Cell Therapeutics said FDA granted Orphan Drug designation to Opaxio paclitaxel poliglumex to treat glioblastoma multiforme (GBM). The polyglutamate polymer formulation...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >